Periodontal Biology Laboratory, Faculty of Dentistry, Universidad de Chile, Santiago, Chile.
Department of Periodontology, School of Dentistry, Universidad Científica del Sur, Lima, Peru.
J Periodontol. 2021 Jan;92(1):123-136. doi: 10.1002/JPER.20-0055. Epub 2020 Jun 30.
During periodontitis, tooth-supporting alveolar bone is resorbed when there is an increased expression of the pro-osteolytic factor termed receptor activator of nuclear factor κB ligand (RANKL), which is responsible for osteoclast differentiation and activation. In periodontitis-affected tissues, the imbalance between T-helper type-17 (Th17) and T-regulatory (Treg) lymphocyte activity favors this RANKL overexpression. In this context, immunotherapeutic strategies aimed at modulating this Th17/Treg imbalance could eventually arrest the RANKL-mediated alveolar bone loss. Boldine has been reported to protect from pathological bone loss during rheumatoid arthritis and osteoporosis, whose pathogenesis is associated with a Th17/Treg imbalance. However, the effect of boldine on alveolar bone resorption during periodontitis has not been elucidated yet. This study aimed to determine whether boldine inhibits alveolar bone resorption by modulating the Th17/Treg imbalance during periodontitis.
Mice with ligature-induced periodontitis were orally treated with boldine (10/20/40 mg/kg) for 15 consecutive days. Non-treated periodontitis-affected mice and non-ligated mice were used as controls. Alveolar bone loss was analyzed by micro-computed tomography and scanning electron microscopy. Osteoclasts were quantified by histological identification of tartrate-resistant acid phosphatase-positive cells. Production of RANKL and its competitive antagonist osteoprotegerin (OPG) were analyzed by ELISA, quantitative polymerase chain reaction (qPCR), and immunohistochemistry. The Th17 and Treg responses were analyzed by quantifying the T-cell frequency and number by flow cytometry. Also, the expression of their signature transcription factors and cytokines were quantified by qPCR.
Boldine inhibited the alveolar bone resorption. Consistently, boldine caused a decrease in the osteoclast number and RANKL/OPG ratio in periodontal lesions. Besides, boldine reduced the Th17-lymphocyte detection and response and increased the Treg-lymphocyte detection and response in periodontitis-affected tissues.
Boldine, administered orally, inhibited the alveolar bone resorption and modulated the Th17/Treg imbalance during experimental periodontitis.
在牙周炎中,当促骨吸收因子核因子 κB 受体激活剂配体(RANKL)表达增加时,支持牙齿的牙槽骨会被吸收,该因子负责破骨细胞的分化和激活。在受牙周炎影响的组织中,辅助性 T 细胞 17(Th17)和调节性 T(Treg)淋巴细胞活性的失衡有利于这种 RANKL 的过度表达。在这种情况下,旨在调节这种 Th17/Treg 失衡的免疫治疗策略最终可能会阻止 RANKL 介导的牙槽骨丢失。波棱瓜子已被报道可在类风湿性关节炎和骨质疏松症中保护病理性骨丢失,其发病机制与 Th17/Treg 失衡有关。然而,波棱瓜子对牙周炎期间牙槽骨吸收的影响尚未阐明。本研究旨在确定波棱瓜子是否通过调节牙周炎期间 Th17/Treg 失衡来抑制牙槽骨吸收。
通过结扎诱导牙周炎的小鼠连续 15 天口服波棱瓜子(10/20/40mg/kg)进行治疗。未治疗的牙周炎受影响的小鼠和未结扎的小鼠用作对照。通过微计算机断层扫描和扫描电子显微镜分析牙槽骨丢失。通过组织学鉴定抗酒石酸酸性磷酸酶阳性细胞来定量破骨细胞。通过 ELISA、定量聚合酶链反应(qPCR)和免疫组织化学分析 RANKL 及其竞争性拮抗剂骨保护素(OPG)的产生。通过流式细胞术定量 T 细胞频率和数量来分析 Th17 和 Treg 反应。此外,通过 qPCR 定量其特征转录因子和细胞因子的表达。
波棱瓜子抑制了牙槽骨吸收。一致地,波棱瓜子导致牙周病变中破骨细胞数量和 RANKL/OPG 比值减少。此外,波棱瓜子减少了牙周炎组织中 Th17 淋巴细胞的检测和反应,并增加了 Treg 淋巴细胞的检测和反应。
口服给予波棱瓜子可抑制实验性牙周炎中的牙槽骨吸收并调节 Th17/Treg 失衡。